Expanding Access to Hormonal IUDs in South Africa through Generic Innovation
The launch of AVIBELA marks a significant milestone for hormonal IUD South Africa, introducing the country’s first generic levonorgestrel 52 mg intrauterine device. Developed by Medicines360 and commercialized in partnership with Pharma Dynamics, AVIBELA is more than 99% effective at preventing pregnancy for up to six years and is also indicated for the treatment of heavy menstrual bleeding (HMB).
The most impactful aspect of this launch is its potential to reduce the financial obstacle that has historically limited hormonal IUD adoption in South Africa. By introducing a quality-assured, clinically equivalent generic option, the partnership seeks to shift utilization patterns away from short-acting methods toward more reliable long-acting reversible contraception (LARC).
South Africa’s Contraceptive Reality
Despite nine million women using modern contraception, IUD uptake remains at approximately 1.9% of the national method mix, while an estimated 64% of pregnancies are unplanned. AVIBELA directly addresses persistent barriers of upfront cost, limited product availability, and provider training gaps.
Economic Impact on Women’s Health
From a health-system perspective, increasing LARC uptake through an affordable generic hormonal IUD can lower the overall cost burden associated with unplanned pregnancies, repeat abortions, and frequent dispensing of short-acting methods. This partnership model offers a replicable template for expanding access in similar middle-income markets.
